MedTrace Logo

Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC

NCT06864624 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2025-07-25

No results posted yet for this study

Summary

This is a single-arm, phase 2 study to investigate the efficacy and safety of sunvozertinib as neoadjuvant and adjuvant treatment for stage II-IIIB non-small-cell lung cancer patients with EGFR exon20 insertion mutation.

Conditions

Interventions

DRUG

Sunvozertinib

Neoadjuvant stage: 300mg for 12 weeks Adjuvant stage: 300mg for first 4 weeks, then 150mg for up to 2 years

Sponsors & Collaborators

  • Dizal (Jiangsu) Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Tang-Du Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-18
Primary Completion
2026-12-31
Completion
2029-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06864624 on ClinicalTrials.gov